These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Marcom PK; Isaacs C; Harris L; Wong ZW; Kommarreddy A; Novielli N; Mann G; Tao Y; Ellis MJ Breast Cancer Res Treat; 2007 Mar; 102(1):43-9. PubMed ID: 16897431 [TBL] [Abstract][Full Text] [Related]
8. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant pegylated liposomal doxorubicin in combination with cisplatin and infusional fluoruracil (CCF) with and without endocrine therapy in locally advanced primary or recurrent breast cancer. Torrisi R; Montagna E; Scarano E; Dellapasqua S; Cancello G; Iorfida M; Luini A; Veronesi P; Viale G; Goldhirsch A; Colleoni M Breast; 2011 Feb; 20(1):34-8. PubMed ID: 20638282 [TBL] [Abstract][Full Text] [Related]
10. [Herceptin monotherapy in HER2(+) recurrent breast carcinoma]. Eidtmann H Onkologie; 2002 Dec; 25 Suppl 5():14-5. PubMed ID: 23573613 [No Abstract] [Full Text] [Related]
11. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Ibrahim NK; Yariz KO; Bondarenko I; Manikhas A; Semiglazov V; Alyasova A; Komisarenko V; Shparyk Y; Murray JL; Jones D; Senderovich S; Chau A; Erlandsson F; Acton G; Pegram M Clin Cancer Res; 2011 Nov; 17(21):6822-30. PubMed ID: 21878535 [TBL] [Abstract][Full Text] [Related]
12. A woman with breast cancer and severe impaired lactose tolerance: an intriguing therapeutic dilemma. Zagouri F; Dimitrakakis C; Dimopoulos MA; Tsigginou A; Antsaklis A; Papadimitriou CA Breast J; 2012; 18(6):628-9. PubMed ID: 23009609 [No Abstract] [Full Text] [Related]
13. Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03). Koeberle D; Ruhstaller T; Jost L; Pagani O; Zaman K; von Moos R; Oehlschlegel C; Crowe S; Pilop C; Thuerlimann B; Endocr Relat Cancer; 2011 Apr; 18(2):257-64. PubMed ID: 21317203 [TBL] [Abstract][Full Text] [Related]
14. Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer. Guarneri V Expert Rev Anticancer Ther; 2009 Nov; 9(11):1549-57. PubMed ID: 19895239 [TBL] [Abstract][Full Text] [Related]
15. Expanded use of Herceptin. FDA Consum; 2007; 41(2):4-5. PubMed ID: 17590893 [No Abstract] [Full Text] [Related]
16. Inappropriate ATAC on tamoxifen. Ucci G Lancet Oncol; 2008 Apr; 9(4):314-5. PubMed ID: 18374286 [No Abstract] [Full Text] [Related]
17. Neoadjuvant chemotherapy and targeted therapies: a promising strategy. Metzger-Filho O; de Azambuja E J Natl Cancer Inst Monogr; 2011; 2011(43):116-9. PubMed ID: 22043056 [TBL] [Abstract][Full Text] [Related]
18. Case records of the Massachusetts General Hospital. Case 16-2012. A 32-year-old woman with HER2-positive breast cancer. Baselga J; Smith BL; Rafferty EA; Bombonati A N Engl J Med; 2012 May; 366(21):2018-26. PubMed ID: 22621630 [No Abstract] [Full Text] [Related]
19. A randomized controlled trial comparing primary tumour resection plus systemic therapy with systemic therapy alone in metastatic breast cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017. Shien T; Nakamura K; Shibata T; Kinoshita T; Aogi K; Fujisawa T; Masuda N; Inoue K; Fukuda H; Iwata H Jpn J Clin Oncol; 2012 Oct; 42(10):970-3. PubMed ID: 22833684 [TBL] [Abstract][Full Text] [Related]
20. Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy. Park IH; Ro J; Lee KS; Kim EA; Kwon Y; Nam BH; Jung SY; Lee S; Kim SW; Kang HS J Clin Oncol; 2010 Jun; 28(16):2705-11. PubMed ID: 20421538 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]